GlassScriptPhysician profile
Sirinan Tazen
NPI 1649473794
$2,549.93
in general payments reported to CMS, 2019-2025
20 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,581 · 2024: $350 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.59 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,460.74 | 2022 | |
| Eisai INC. | $202.26 | 2024-2025 | |
| Pfizer INC. | $161.61 | 2024-2025 | |
| Abbvie INC. | $134.87 | 2024-2025 | |
| Lilly USA, LLC | $105.37 | 2024-2025 | Amyvid, Kisunla |
| Neurelis, INC. | $71.59 | 2024-2025 | Valtoco |
| Boston Scientific Corporation | $50.38 | 2022 | |
| Sk Life Science, INC. | $48.26 | 2025 | |
| Amneal Pharmaceuticals LLC | $46.51 | 2024-2025 | Crexont, Ongentys |
| Genentech USA, INC. | $38.49 | 2025 | Ocrevus Zunovo |
| Avanir Pharmaceuticals, INC. | $32.96 | 2022 | |
| Sumitomo Pharma America, INC. | $28.83 | 2024 | Aptiom |
| Neurocrine Biosciences, INC. | $28.39 | 2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $25.13 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $24.66 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $24.27 | 2025 | Horizant |
| Biogen, INC. | $18.21 | 2024 | Tysabri, Vumerity |
| Ucb, INC. | $18.00 | 2025 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $17.20 | 2024 | Ajovy |
| Avion Pharmaceuticals | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirinan Tazen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.